VIATRIS INC. Gain (Loss) Related to Litigation Settlement
VIATRIS INC. (VTRS) reported Gain (Loss) Related to Litigation Settlement of -$73.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossRelatedToLitigationSettlement · last filed 2026-08-06
- VIATRIS INC. gain (loss) related to litigation settlement for the quarter ending 2026-06-30 was -$73.20M, a 253.78% decline year-over-year.
- VIATRIS INC. gain (loss) related to litigation settlement for the quarter ending 2026-03-31 was -$53.50M, a 172.79% decline year-over-year.
- VIATRIS INC. gain (loss) related to litigation settlement for the quarter ending 2025-12-31 was $3.10M.
- VIATRIS INC. gain (loss) related to litigation settlement for the quarter ending 2025-09-30 was -$55.70M.
- VIATRIS INC. gain (loss) related to litigation settlement for fiscal 2025 was $68.50M.
- VIATRIS INC. gain (loss) related to litigation settlement for fiscal 2024 was -$350.90M.
- VIATRIS INC. gain (loss) related to litigation settlement for fiscal 2023 was -$111.60M.
- VIATRIS INC. gain (loss) related to litigation settlement for fiscal 2022 was -$4.40M.
| Period end | Gain (Loss) Related to Litigation Settlement 3 month | Gain (Loss) Related to Litigation Settlement 6 month | Gain (Loss) Related to Litigation Settlement 9 month | Gain (Loss) Related to Litigation Settlement 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$73.20M 10-Q · filed 2026-08-06 | -$126.70M 10-Q · filed 2026-08-06 | -$123.60M derived: sum of 3 quarters · filed 2026-08-06 | -$179.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$53.50M 10-Q · filed 2026-05-07 | -$50.40M derived: sum of 2 quarters · filed 2026-05-07 | -$106.10M derived: sum of 3 quarters · filed 2026-05-07 | -$58.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$52.60M derived: sum of 2 quarters · filed 2026-02-26 | -$5.00M derived: sum of 3 quarters · filed 2026-08-06 | $68.50M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$55.70M 10-Q · filed 2025-11-06 | -$8.10M derived: sum of 2 quarters · filed 2026-08-06 | $65.40M 10-Q · filed 2025-11-06 | -$46.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $47.60M 10-Q · filed 2026-08-06 | $121.10M 10-Q · filed 2026-08-06 | $9.50M derived: sum of 3 quarters · filed 2026-08-06 | -$22.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $73.50M 10-Q · filed 2026-05-07 | -$38.10M derived: sum of 2 quarters · filed 2026-05-07 | -$69.60M derived: sum of 3 quarters · filed 2026-05-07 | -$200.60M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$111.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$143.10M derived: sum of 2 quarters · filed 2026-02-26 | -$274.10M derived: sum of 3 quarters · filed 2026-02-26 | -$350.90M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$31.50M 10-Q · filed 2025-11-06 | -$162.50M derived: sum of 2 quarters · filed 2025-11-06 | -$239.30M 10-Q · filed 2025-11-06 | -$387.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$131.00M 10-Q · filed 2025-08-07 | -$207.80M 10-Q · filed 2025-08-07 | -$355.90M derived: sum of 3 quarters · filed 2026-02-26 | -$329.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$76.80M 10-Q · filed 2025-05-08 | -$224.90M derived: sum of 2 quarters · filed 2026-02-26 | -$198.80M derived: sum of 3 quarters · filed 2026-02-26 | -$187.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$148.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$122.00M derived: sum of 2 quarters · filed 2026-02-26 | -$111.00M derived: sum of 3 quarters · filed 2026-02-26 | -$111.60M 10-K · filed 2026-02-26 |
| 2023-09-30 | $26.10M 10-Q · filed 2024-11-07 | $37.10M derived: sum of 2 quarters · filed 2024-11-07 | $36.50M 10-Q · filed 2024-11-07 | $45.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $11.00M 10-Q · filed 2024-08-08 | $10.40M 10-Q · filed 2024-08-08 | $19.20M derived: sum of 3 quarters · filed 2025-02-27 | $23.10M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$600.00K 10-Q · filed 2024-05-09 | $8.20M derived: sum of 2 quarters · filed 2025-02-27 | $12.10M derived: sum of 3 quarters · filed 2025-02-27 | $1.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $8.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $12.70M derived: sum of 2 quarters · filed 2025-02-27 | $1.80M derived: sum of 3 quarters · filed 2025-02-27 | -$4.40M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.90M 10-Q · filed 2023-11-08 | -$7.00M derived: sum of 2 quarters · filed 2023-11-08 | -$13.20M 10-Q · filed 2023-11-08 | -$287.10M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$10.90M 10-Q · filed 2023-08-07 | -$17.10M 10-Q · filed 2023-08-07 | -$291.00M derived: sum of 3 quarters · filed 2024-02-28 | -$300.40M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$6.20M 10-Q · filed 2023-05-08 | -$280.10M derived: sum of 2 quarters · filed 2024-02-28 | -$289.50M derived: sum of 3 quarters · filed 2024-02-28 | -$312.50M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$273.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$283.30M derived: sum of 2 quarters · filed 2024-02-28 | -$306.30M derived: sum of 3 quarters · filed 2024-02-28 | -$329.20M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$9.40M 10-Q · filed 2022-11-07 | -$32.40M derived: sum of 2 quarters · filed 2022-11-07 | -$55.30M 10-Q · filed 2022-11-07 | -$126.60M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$23.00M 10-Q · filed 2022-08-08 | -$45.90M 10-Q · filed 2022-08-08 | -$117.20M derived: sum of 3 quarters · filed 2023-02-27 | -$136.10M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$22.90M 10-Q · filed 2022-05-09 | -$94.20M derived: sum of 2 quarters · filed 2023-02-27 | -$113.10M derived: sum of 3 quarters · filed 2023-02-27 | -$128.90M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$71.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$90.20M derived: sum of 2 quarters · filed 2023-02-27 | -$106.00M derived: sum of 3 quarters · filed 2023-02-27 | -$107.80M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$18.90M 10-Q · filed 2021-11-08 | -$34.70M derived: sum of 2 quarters · filed 2021-11-08 | -$36.50M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$15.80M 10-Q · filed 2021-08-09 | -$17.60M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$1.80M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $21.40M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $49.50M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |